Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy

Open access
Sathekge, Mike, Bruchertseifer, Frank, Vorster, Mariza, Lawal, Ismaheel O., Knoesen, Otto, Mahapane, Johncy, Davis, Cindy, Reyneke, Florette, Maes, Alex, Kratochwil, Clemens, Lengana, Thabo, Giesel, Frederik L., Van de Wiele, Christophe, Morgenstern, Alfred · 2020 · Journal of Nuclear Medicine

Abstract

Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA), making this antigen a suitable target for radioligand therapy of the disease. Here we report on our experience with a series of 73 castration-resistant prostate carcinoma patients treated with 225Ac-PSMA-617, identifying variables predictive for overall survival (OS) and progression-free survival (PFS) after 225Ac-PSMA-617 treatment. Methods:225Ac-PSMA-617 was administered to patients who had metastatic castration-resistant prostate carcinoma and who had exhausted available therapy options for their disease. Full blood count, glomerular filtration rate, and liver function test were obtained at baseline and on follow-up for evaluation of toxicity. 68Ga-PSMA PET/CT was obtained at baseline, before every treatment cycle, and on follow-up for selection of patients for treatment, to determine the activity of the treatment agent to be administered, and for response assessment. Serial prostate-specific antigen (PSA) was obtained for PSA response assessment. Results: Seventy-three men (mean age, 69 y; range, 45–85 y) with metastatic castration-resistant prostate carcinoma were treated with 210 cycles of 225Ac-PSMA-617. In 70% of patients, a PSA decline of greater than or equal to 50% was obtained; 82% of patients had any PSA decline. In 29% of patients, all lesions on 68Ga-PSMA PET resolved in response to treatment. During follow-up, 23 patients experienced disease progression, whereas 13 patients died from their disease. The estimated median PFS and OS were 15.2 mo (95% CI, 13.1–17.4) and 18 mo (95% CI, 16.2–19.9), respectively. In univariate analyses, factors such as baseline PSA, any PSA decline, PSA decline of greater than or equal to 50%, prior chemotherapy, prior radiation therapy, and baseline hemoglobin level were associated with longer PFS and OS (all Ps < 0.05). In multivariate analyses, there was a negative association between prior 177Lu-PSMA therapy and PFS, and a positive association between PSA decline of greater or equal to 50% and PFS. Only a PSA decline of greater than or equal to 50% remained significantly associated with OS on multivariate analyses. Xerostomia was seen in 85% of patients but was not severe enough to warrant discontinuing treatment. Anemia was seen in 27 patients; no patients had grade IV bone marrow toxicity. Renal failure of grade III or IV was seen in 5 patients with baseline renal impairment. Conclusion: In this study, a PSA decline of greater than or equal to 50% after treatment with 225Ac-PSMA-617 was proven by multivariate analyses to be significantly associated with OS and PFS. Furthermore, previous 177Lu-PSMA treatment was negatively associated with PFS in both univariate and multivariate analyses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2967/jnumed.119.229229

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

    Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408 · cited 1×

    “223Ra-dichloride is an approved a-emitting radionuclide with survival benefit in patients with predominantly bone metastases of prostate cancer (6).”
    Background

Show all 1 references

Cited by

See all 193

Metadata

Authors
Sathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Reyneke, F., Maes, A., Kratochwil, C., Lengana, T., Giesel, F. L., Van de Wiele, C., & Morgenstern, A.
Venue
Journal of Nuclear Medicine
Published
2019-05-17
Volume
61
Issue
1
Pages
62-69
ISSN
  • 0161-5505 (ISSN-L)
  • 2159-662X
OpenAlex
W2945915427
Cited by
193
References
1
FWCI
14.40
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy. https://app.cochat.ai/papers/10.2967/jnumed.119.229229
The paper
Sathekge, M., Bruchertseifer, F., Vorster, M., Lawal, I. O., Knoesen, O., Mahapane, J., Davis, C., Reyneke, F., Maes, A., Kratochwil, C., Lengana, T., Giesel, F. L., Van de Wiele, C., & Morgenstern, A. (2020). Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.119.229229

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.